Aprea Therapeutics, Inc.

For the period ended Mar 31, 2026. Filed May 13, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 13, 2026

APRE$0.50-3.2%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 6. Exhibits

Exhibit Index


Exhibit
Number		Description of Document
4.1		Form of Pre-Funded Warrant (January 2026 Offering) (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K filed on January 29, 2026).

4.2		Form of Common Warrant (January 2026 Offering) (incorporated by reference to Exhibit 4.2 to the Current Report on Form 8-K filed on January 29, 2026).

4.3		Form of Pre-Funded Warrant (March 2026 Offering) (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K filed on March 30, 2026).
4.4		Form of Common Warrant (March 2026 Offering) (incorporated by reference to Exhibit 4.2 to the Current Report on Form 8-K filed on March 30, 2026).

10.1		Form of Securities Purchase Agreement (January 2026 Offering) (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on January 29, 2026).

10.2		Form of Registration Rights Agreement (January 2026 Offering) (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed on January 29, 2026).

10.3		Form of Placement Agency Agreement (January 2026 Offering) (incorporated by reference to Exhibit 10.3 to the Current Report on Form 8-K filed on January 29, 2026).

10.4		Form of Amendment to the Securities Purchase Agreement (January 2026 Offering) (incorporated by reference to Exhibit 10.4 to the Current Report on Form 8-K filed on January 29, 2026).

10.5		Form of Securities Purchase Agreement (March 2026 Offering) (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on March 30, 2026).

10.6		Form of Registration Rights Agreement (March 2026 Offering) (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed on March 30, 2026).

10.7		Form of Placement Agency Agreement (March 2026 Offering) (incorporated by reference to Exhibit 10.3 to the Current Report on Form 8-K filed on March 30, 2026).

10.8		Form of Lock-Up Agreement (March 2026 Offering) (incorporated by reference to Exhibit 10.4 to the Current Report on Form 8-K filed on March 30, 2026).

10.9		Form of Amendment to the Securities Purchase Agreement (incorporated by reference to Exhibit 10.5 to the Current Report on Form 8-K filed on March 30, 2026).

31.1+		Certification of the Registrant’s Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2+		Certification of the Registrant’s Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1*		Certification of the Registrant’s Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.


Exhibit
Number		Description of Document
32.2*		Certification of the Registrant’s Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS		Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

101.SCH		XBRL Taxonomy Extension Schema With Embedded Linkbase Documents.

104		Cover Page Interactive Data File (formatted as Inline XBRL with applicable taxonomy extension information contained in Exhibits 101).

*	The certifications furnished in Exhibit 32.1 and Exhibit 32.2 hereto are deemed to accompany this Quarterly Report and will not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, except to the extent that the registrant specifically incorporates it by reference.

+	Filed herewith

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


Date: May 13, 2026	Aprea Therapeutics, Inc.

	By:	/s/ Oren Gilad
		Oren Gilad, Ph.D.
		President and Chief Executive Officer (Principal Executive Officer)

Date: May 13, 2026

	By:	/s/ John P. Hamill
		John P. Hamill
		Senior Vice President and Chief Financial Officer (Principal Financial and Accounting Officer)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.